

Table XXV. Sclerotherapy in patient with thrombophilia.

1 article,1 RCT

Treatment	Reference	Summary
<p>Anticoagulation (LMWH vs. Warfarin) in patients with documented thrombophilia and treated by UGFS for varices</p>	<p>Hamel-Desnos CM, Gillet JL, Desnos PR, Allaert PA. Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. <i>Phlebology</i>. 2009;24:176-182.</p>	<p>Multi-center study. 105 patients, CEAP classification C1-C6 presenting thrombophilia. Exclusion criteria detailed - Factor V mutation (heterozygous and homozygous) - Factor II mutation - High factor VIII and combination of 2 factors. Group H: nadoparin 4000 UI simultaneously with UGFS + compression therapy 15-20 mmHg for 4 weeks. Group W: warfarin 1mg per day 4 weeks after UGFS + compression therapy 15-20 mmHg for 4 weeks. Results at follow-up: No episodes of symptomatic deep vein thrombosis (DVT) or pulmonary embolism occurred; no instances of DVT were revealed by US monitoring.</p>

Abbreviations:

LMWH= low molecular weight heparin; US =ultrasound; UGFS= ultrasound guided foam sclerotherapy

